Lexaria Extends Pharma Deal for GLP-1 Drug Delivery Tech

Lexaria Bioscience Corp. (NASDAQ: LEXX) has announced the extension of its Material Transfer Agreement (MTA) with an undisclosed pharmaceutical company, referred to as PharmaCO, through December 31, 2026. The original agreement, entered into on August 30, 2024, was designed to evaluate Lexaria’s patented DehydraTECHTM technology in a pre-clinical setting. The extension accommodates the time needed for PharmaCO to receive and review Lexaria’s 2026 research and development results related to GLP-1 drugs, which are pivotal for treating metabolic disorders like diabetes and obesity. This move allows both parties to continue their collaborative relationship under the MTA, keep the temporary exclusive license active and in force, and plan further strategic discussions with PharmaCO’s human clinical and business development teams.

Over the past 12 months, Lexaria has made significant strides in its GLP-1 development program, including the launch of three new studies: Human Study #7, Animal Study #1, and Animal Study #2. All these studies are fully funded and currently in progress, with results expected during the third and fourth quarters of 2026. These studies aim to provide comprehensive evidence to support further collaboration and potential licensing of Lexaria’s DehydraTECH technology, which has repeatedly demonstrated the ability to increase bio-absorption, reduce side effects, and deliver drugs more effectively across the blood-brain barrier.

Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted worldwide. The company’s DehydraTECH platform is a patented drug delivery formulation and processing technology that enhances oral drug delivery. The extension of this MTA underscores the growing interest in Lexaria’s technology and its potential to revolutionize the delivery of GLP-1 drugs, a rapidly expanding market. The company continues to focus on advancing its research and building strategic partnerships to bring its innovative solutions to market.